Back to Search
Start Over
CDK4/6 Inhibitor Biomarker Research: Are We Barking Up the Wrong Tree?
- Source :
-
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Jan 01; Vol. 26 (1), pp. 3-5. Date of Electronic Publication: 2019 Nov 05. - Publication Year :
- 2020
-
Abstract
- CDK4/6 inhibitors have emerged as a significant advance for the treatment of patients with advanced estrogen receptor-positive breast cancer. However, the identification of predictive markers that optimize their use is proving harder than expected. In this commentary we advocate for unbiased discovery and a collaborative approach across trials. See related article by Finn et al., p. 110 .<br /> (©2019 American Association for Cancer Research.)
Details
- Language :
- English
- ISSN :
- 1557-3265
- Volume :
- 26
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Clinical cancer research : an official journal of the American Association for Cancer Research
- Publication Type :
- Academic Journal
- Accession number :
- 31690650
- Full Text :
- https://doi.org/10.1158/1078-0432.CCR-19-3119